Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors - Test2 - elhamkhani - TriplyDB

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

http://www.wikidata.org/entity/Q37275810

about

Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors Inhibitors of cyclin-dependent kinases as cancer therapeutics.Transcriptional Addiction in Cancer.Super-Enhancer-Driven Transcriptional Dependencies in Cancer.Advances of small molecule targeting of kinases.Structure-Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent.CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.The emerging roles of CDK12 in tumorigenesis.ER stress signaling promotes the survival of cancer 'persister cells' tolerant to EGFR tyrosine kinase inhibitors.BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer.Chromatin dependencies in cancer and inflammation.CDK regulation of transcription by RNAP II: Not over 'til it's over?CDK9 inhibitors in acute myeloid leukemia.A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response.Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation.

P2860

Q28817622-48C5CD19-EABD-4107-8C53-4A2922387942 Q33859476-CD992569-28F5-4D37-9E3A-BD374E1504A8 Q37622508-CA805A71-D237-42C6-8AD2-F89D67F5CE63 Q39125016-B0E5E3A6-FAE5-4586-9410-0A02F18DEBE9 Q39130428-5EC6C60A-18B5-4860-B00B-4F6212B01663 Q39441366-A7FA2053-C08C-4EE1-964F-F857D1BDCFE2 Q39450797-5001FF2E-CF4D-42C6-8535-840E280AF43D Q40064078-E774B2B3-EC63-4D31-B956-5C1FFA83257C Q40950455-B5DEADE9-FF22-428C-901B-E0CE0306A11A Q42367759-0260E0AC-96E8-4D2D-82A7-672149EB9227 Q46006387-4FACAD91-AC22-4771-8375-3C3860D549BA Q47155353-AB635C9F-0F9B-4250-A5C6-9A99BB46032A Q47273602-728CD7E6-F84F-493F-A734-390DE8C42F30 Q47660928-8A39AE0B-7AB4-46C5-AE40-3B3D90A427BF Q47671139-8C69F0C8-7F3E-4761-85C9-C958277CB0B3 Q48100900-45FC3E68-EF27-42DB-AEE5-EA9E23F567E2 Q48188305-801F744B-F4F7-4228-9E7E-0E77A00A1794 Q49565575-DB61527D-74BF-4888-9033-6DFBC397061C Q50015077-BB3200B4-0F62-47D7-A137-4F8BD9155E79 Q50318294-B2B73F05-5345-407A-9B5C-812D8BA2219C Q50422144-39495A4E-64E3-4208-8AE3-B1875632989D Q54979117-A01C6F84-E6F7-42BC-A548-BDC7ED48CA3C

P2860

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

http://www.wikidata.org/entity/Q37275810

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

@en

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.

@nl

type

label

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

@en

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.

@nl

prefLabel

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

@en

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.

@nl

P1433

Q37275810-9B935D30-5D4C-4C94-9F3C-FC7CC58C5D78

P1476

Q37275810-3F7E073D-B7B6-45FF-B96B-0E4887D9C413

P2093

Q37275810-16D566E5-6A38-4204-BA5E-BEBCA435816B

Q37275810-347A51BD-270A-4BB0-B086-EF28F1704BF1

Q37275810-4FAD5CB0-51C3-4B64-9AD5-01EF1FB4BC8F

Q37275810-5AFA9AE1-148B-4345-A0B7-28029D83F59F

Q37275810-72E3717E-1D4C-41A6-881F-93F7A2633FB1

Q37275810-7A646C08-E39A-4619-8C17-58F5AA7C0D2E

Q37275810-89D64DE0-B0CA-452F-A7B1-2A6FF4299DC9

Q37275810-A1749C21-D517-4A2E-A950-A1BA5B34DC39

Q37275810-A2FFDEBD-F870-4381-BE25-6826770E62BD

Q37275810-A94344FF-64D3-4328-B920-2E0E6B0B2307

P2860

Q37275810-02981A68-D6B1-462A-A74A-D15303AD8DE7

Q37275810-0416A5B6-7937-42D7-AC8C-395535C28508

Q37275810-05992B65-F494-44AF-ACE9-86BFA62D6C27

Q37275810-0CED4EF0-FEEB-4C82-8282-BD3B7385E842

Q37275810-0D4E53EB-0DB7-4F99-887A-4769B1C3CA25

Q37275810-0E759750-D3F2-4C9F-98CE-8F375B1C3EFB

Q37275810-0F0E2724-064C-40DA-B37D-167C16BB2A5C

Q37275810-277CF635-1164-40D8-A88E-A7BBC4F4CD0C

Q37275810-27BFFD03-B891-4F66-9CF8-875BD83A3BC1

Q37275810-2A5D12E5-B7C7-4D8B-BFA9-6651B8FD76D0

P2888

Q37275810-10DADE14-8FE3-437E-8CFF-15969ADA1349

P304

Q37275810-7365C065-866D-400A-BD93-C080DA13D050

P31

Q37275810-488D4CE1-3E01-4370-BA12-A8C1231CBADB

P356

Q37275810-BB3808E2-95A0-496F-AC9A-93EDF4329DB4

P433

Q37275810-3DBD38EA-8E27-4BF1-8E80-6C00EAA40A5D

P478

Q37275810-6335AFA9-7231-4E4B-9709-828C17C15A0E

P50

Q37275810-19C93A41-096A-4E9F-B420-C5C8D2CEB795

Q37275810-1B551B3A-D818-45AB-A9C0-B6E26922079D

Q37275810-261E4410-CAEB-44FD-AFC0-9FAA0F1BCF78

Q37275810-B78A4D79-B64C-44D9-937C-EC94A5E8A124

Q37275810-BAA9FADA-5148-4F4A-BD16-A0D4C951BF15

Q37275810-D7777E6D-98C3-45A0-A69C-FC3F1C13FC27

P577

Q37275810-C14CB522-D656-40A5-9EF0-2DA9DAB5E1E6

P698

Q37275810-4C6D0AC3-A498-4B3D-9B2A-3CEB8434B7A3

P932

Q37275810-E1A1F484-35C6-4503-9B4B-8BFD3229D411

P356

P1433

Nature Chemical Biology

P1476

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors

@en

P2093

Ann K Greifenberg

http://www.w3.org/2001/XMLSchema#string

Arno L Greenleaf

http://www.w3.org/2001/XMLSchema#string

Bartlomiej Bartkowiak

http://www.w3.org/2001/XMLSchema#string

Calla M Olson

http://www.w3.org/2001/XMLSchema#string

Jarrod A Marto

http://www.w3.org/2001/XMLSchema#string

Mingfeng Hao

http://www.w3.org/2001/XMLSchema#string

Nancy M Hannett

http://www.w3.org/2001/XMLSchema#string

Nicholas Kwiatkowski

http://www.w3.org/2001/XMLSchema#string

Sarah E Dixon-Clarke

http://www.w3.org/2001/XMLSchema#string

Scott B Ficarro

http://www.w3.org/2001/XMLSchema#string

P2860

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome

Model-based analysis of ChIP-Seq (MACS)

The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes

Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II

CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1

Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

MolProbity: all-atom structure validation for macromolecular crystallography

Discovery of Potent and Selective Covalent Inhibitors of JNK

The structure and substrate specificity of human Cdk12/Cyclin K

P2888

P304

876-884

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCHEMBIO.2166

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan M Elkins

Brian J. Abraham

Nathanael S Gray

P577

2016-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27571479

http://www.w3.org/2001/XMLSchema#string

P932

5033074

http://www.w3.org/2001/XMLSchema#string